Gilder Gagnon Howe & Co. LLC Has $54.37 Million Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Gilder Gagnon Howe & Co. LLC grew its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 9.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 3,902,991 shares of the company's stock after acquiring an additional 349,153 shares during the period. Gilder Gagnon Howe & Co. LLC owned about 3.33% of Arcutis Biotherapeutics worth $54,369,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in ARQT. Venturi Wealth Management LLC purchased a new position in shares of Arcutis Biotherapeutics during the fourth quarter worth $46,000. Cibc World Markets Corp purchased a new position in Arcutis Biotherapeutics during the 4th quarter valued at about $140,000. Summit Investment Advisors Inc. grew its position in Arcutis Biotherapeutics by 8.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 11,245 shares of the company's stock valued at $157,000 after acquiring an additional 837 shares in the last quarter. LVW Advisors LLC acquired a new stake in shares of Arcutis Biotherapeutics during the fourth quarter worth about $166,000. Finally, Syon Capital LLC purchased a new position in shares of Arcutis Biotherapeutics in the fourth quarter valued at approximately $189,000.

Insider Transactions at Arcutis Biotherapeutics

In other news, insider Masaru Matsuda sold 8,338 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $12.70, for a total value of $105,892.60. Following the completion of the sale, the insider now owns 178,692 shares of the company's stock, valued at approximately $2,269,388.40. The trade was a 4.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Todd Franklin Watanabe sold 1,500 shares of Arcutis Biotherapeutics stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $17.52, for a total transaction of $26,280.00. Following the completion of the transaction, the insider now directly owns 927,414 shares of the company's stock, valued at $16,248,293.28. This trade represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 46,099 shares of company stock valued at $631,256 over the last quarter. Company insiders own 9.50% of the company's stock.

Arcutis Biotherapeutics Price Performance

Shares of Arcutis Biotherapeutics stock traded down $0.15 on Thursday, hitting $14.76. The company's stock had a trading volume of 701,495 shares, compared to its average volume of 2,373,742. The company has a quick ratio of 2.38, a current ratio of 2.46 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $1.75 billion, a P/E ratio of -8.26 and a beta of 1.67. Arcutis Biotherapeutics, Inc. has a 52-week low of $6.99 and a 52-week high of $17.75. The firm has a fifty day moving average price of $14.58 and a 200-day moving average price of $12.95.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.19. The firm had revenue of $71.36 million for the quarter, compared to analysts' expectations of $60.52 million. Arcutis Biotherapeutics had a negative return on equity of 119.11% and a negative net margin of 140.97%. On average, equities research analysts expect that Arcutis Biotherapeutics, Inc. will post -1.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ARQT has been the topic of several analyst reports. Guggenheim reiterated a "buy" rating on shares of Arcutis Biotherapeutics in a research note on Thursday, April 3rd. The Goldman Sachs Group lifted their price target on Arcutis Biotherapeutics from $13.00 to $15.00 and gave the stock a "neutral" rating in a report on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and set a $20.00 target price on shares of Arcutis Biotherapeutics in a research report on Wednesday, April 9th. Mizuho upped their price target on Arcutis Biotherapeutics from $20.00 to $21.00 and gave the company an "outperform" rating in a report on Wednesday, February 26th. Finally, HC Wainwright restated a "buy" rating and issued a $19.00 price objective on shares of Arcutis Biotherapeutics in a research note on Thursday, April 3rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $18.80.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.